ARTERA.AI: Keyword Density Checker

Total words: 4007 | 2-word phrases: 1039 | 3-word phrases: 1192 | 4-word phrases: 1254

PAGE INFO

Title	Try to keep the title under 60 characters (66 characters) Personalized Precision Medicine & AI Cancer Therapy \| ArteraAI
Description	Try to keep the meta description between 50 - 160 characters (140 characters) Discover the power of Personalized Precision Medicine & AI Cancer Therapy with ArteraAI. Transforming cancer therapy through innovation.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (50 characters) Cancer is personal. Cancer therapy should be, too.

ONE WORD PHRASES 522 Words

#	Keyword	Frequency	Density
1	the	59	11.30%
2	cancer	46	8.81%
3	and	36	6.90%
4	of	34	6.51%
5	arteraai	32	6.13%
6	to	31	5.94%
7	prostate	29	5.56%
8	for	29	5.56%
9	in	25	4.79%
10	test	23	4.41%

TWO WORD PHRASES 1039 Words

#	Keyword	Frequency	Density
1	prostate cancer	18	1.73%
2	arteraai prostate	11	1.06%
3	of the	9	0.87%
4	the arteraai	9	0.87%
5	prostate test	9	0.87%
6	cancer test	7	0.67%
7	in the	7	0.67%
8	cancer a	7	0.67%
9	and prognostic	6	0.58%
10	learn more	6	0.58%
11	artificial intelligence	6	0.58%
12	for the	6	0.58%
13	cancer the	5	0.48%
14	predictive and	5	0.48%
15	from a	5	0.48%
16	the most	5	0.48%
17	payment rate	5	0.48%
18	for a	4	0.38%
19	multimodal artificial	4	0.38%
20	cancer society	4	0.38%

THREE WORD PHRASES 1192 Words

#	Keyword	Frequency	Density
1	the arteraai prostate	7	0.59%
2	prostate cancer a	6	0.50%
3	arteraai prostate test	6	0.50%
4	for prostate cancer	4	0.34%
5	predictive and prognostic	4	0.34%
6	multimodal artificial intelligence	4	0.34%
7	with biochemical recurrence	3	0.25%
8	patients with biochemical	3	0.25%
9	in radical prostatectomy	3	0.25%
10	risk of metastasis	3	0.25%
11	oncology nccn guidelines	3	0.25%
12	for the arteraai	3	0.25%
13	prostate cancer test	3	0.25%
14	rate for the	3	0.25%
15	guidelines® for prostate	3	0.25%
16	american cancer society	3	0.25%
17	prostate cancer arteraai	3	0.25%
18	clinicians and patients	3	0.25%
19	localized prostate cancer	3	0.25%
20	arteraai prostate cancer	3	0.25%
21	prostate test is	3	0.25%
22	guidelines in oncology	3	0.25%
23	in oncology nccn	3	0.25%
24	the developer of	3	0.25%
25	payment rate for	3	0.25%
26	artificial intelligence mmai	3	0.25%
27	individualized treatment plans	2	0.17%
28	benefit and prognosticate	2	0.17%
29	prognosticate longterm outcomes	2	0.17%
30	and prognosticate longterm	2	0.17%

FOUR WORD PHRASES 1254 Words

#	Keyword	Frequency	Density
1	the arteraai prostate test	4	0.32%
2	rate for the arteraai	3	0.24%
3	in oncology nccn guidelines	3	0.24%
4	guidelines® for prostate cancer	3	0.24%
5	patients with biochemical recurrence	3	0.24%
6	arteraai prostate cancer test	3	0.24%
7	guidelines in oncology nccn	3	0.24%
8	for the arteraai prostate	3	0.24%
9	payment rate for the	3	0.24%
10	the first aibased biomarker	2	0.16%
11	oncology nccn guidelines® for	2	0.16%
12	in oncology nccn guidelines®	2	0.16%
13	practice guidelines in oncology	2	0.16%
14	clinical practice guidelines in	2	0.16%
15	first aibased biomarker to	2	0.16%
16	aibased biomarker to stratify	2	0.16%
17	center logo uw medicine	2	0.16%
18	biomarker to stratify risk	2	0.16%
19	logo uw medicine logo	2	0.16%
20	stratify risk of metastasis	2	0.16%
21	in radical prostatectomy patients	2	0.16%
22	radical prostatectomy patients with	2	0.16%
23	prostatectomy patients with biochemical	2	0.16%
24	national comprehensive cancer network	2	0.16%
25	multimodal artificial intelligence mmai	2	0.16%
26	the developer of multimodal	2	0.16%
27	arteraai the developer of	2	0.16%
28	validating the first aibased	2	0.16%
29	days after receipt of	2	0.16%
30	receipt of the patients	2	0.16%
31	can predict therapy benefit	2	0.16%
32	cancer center logo uw	2	0.16%
33	hutch cancer center logo	2	0.16%
34	fred hutch cancer center	2	0.16%
35	medicine fred hutch cancer	2	0.16%
36	with localized prostate cancer	2	0.16%
37	and prognosticate longterm outcomes	2	0.16%
38	benefit and prognosticate longterm	2	0.16%
39	predict therapy benefit and	2	0.16%
40	attend the 2024 asco	2	0.16%

EXTERNAL LINKS

#	URL	Whois	Check
1	https://www.businesswire.com/news/home/20240304893588/en/ArteraAI-Announced-as-the-First-and-Only-Predictive-Test-for-Therapy-Personalization-in-the-2024-NCCN-Guidelines%C2%AE-for-Prostate-Cancer#new_tab	Whois	businesswire.com
2	https://www.businesswire.com/news/home/20240304893588/en/ArteraAI-Announced-as-the-First-and-Only-Predictive-Test-for-Therapy-Personalization-in-the-2024-NCCN-Guidelines%C2%AE-for-Prostate-Cancer#new_tab	Whois	businesswire.com
3	https://www.urologytimes.com/view/cms-payment-rate-established-for-arteraai-prostate-cancer-test#new_tab	Whois	urologytimes.com
4	https://www.urologytimes.com/view/cms-payment-rate-established-for-arteraai-prostate-cancer-test#new_tab	Whois	urologytimes.com
5	https://conferences.asco.org/am/attend#new_tab	Whois	asco.org
6	https://conferences.asco.org/am/attend#new_tab	Whois	asco.org
7	https://www.businesswire.com/news/home/20240506052855/en/New-Data-Validating-the-First-AI-Based-Biomarker-to-Stratify-Risk-of-Metastasis-in-Radical-Prostatectomy-Patients-with-Biochemical-Recurrence#new_tab	Whois	businesswire.com
8	https://www.businesswire.com/news/home/20240506052855/en/New-Data-Validating-the-First-AI-Based-Biomarker-to-Stratify-Risk-of-Metastasis-in-Radical-Prostatectomy-Patients-with-Biochemical-Recurrence#new_tab	Whois	businesswire.com
9	https://doi.org/10.3322/caac.21660	Whois	doi.org
10	https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34433	Whois	wiley.com
11	https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.108?role=tab	Whois	ascopubs.org
12	https://doi.org/10.3322/caac.21763	Whois	doi.org
13	https://www.businesswire.com/news/home/20240103190751/en/ArteraAI-Receives-Medicare-Payment-Rate-for-the-ArteraAI-Prostate-Cancer-Test#new_tab	Whois	businesswire.com
14	https://www.businesswire.com/news/home/20240103190751/en/ArteraAI-Receives-Medicare-Payment-Rate-for-the-ArteraAI-Prostate-Cancer-Test#new_tab	Whois	businesswire.com
15	https://arteraai.medium.com/how-can-artera-bootstrap-a-new-aws-region-within-hours-9329d12ca224#new_tab	Whois	medium.com
16	https://conferences.asco.org/am/attend#new_tab	Whois	asco.org
17	https://www.goldjournal.net/article/S0090-4295(24)00266-8/abstract#new_tab	Whois	goldjournal.net
18	https://www.linkedin.com/company/arteraai	Whois	linkedin.com
19	https://twitter.com/arteraAI	Whois	twitter.com